{"id":"bkm120-and-erlotinib","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Rash"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"5-20%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BKM120 works by inhibiting the PI3K/AKT signaling pathway, which is involved in cell proliferation and survival. Erlotinib, on the other hand, targets the epidermal growth factor receptor (EGFR), a protein that promotes cell division and growth. By inhibiting these pathways, BKM120 and Erlotinib aim to slow down or stop the growth of cancer cells.","oneSentence":"BKM120 is a PI3K inhibitor, and Erlotinib is a tyrosine kinase inhibitor targeting EGFR.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:24:40.922Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT01570296","phase":"PHASE1","title":"A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2011-10-03","conditions":"Non-Small Cell Lung Cancer, Solid Tumors","enrollment":38},{"nctId":"NCT01487265","phase":"PHASE2","title":"Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2014-03","conditions":"Non Small Cell Lung Cancer","enrollment":37}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Buparlisib (BKM 120) and Tarceva (erlotinib)"],"phase":"phase_2","status":"active","brandName":"BKM120 and Erlotinib","genericName":"BKM120 and Erlotinib","companyName":"SCRI Development Innovations, LLC","companyId":"scri-development-innovations-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BKM120 is a PI3K inhibitor, and Erlotinib is a tyrosine kinase inhibitor targeting EGFR. Used for Non-small cell lung cancer, Pancreatic cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}